

0001213900-25-0119256-K Inspira Technologies OXY B.H.N. Ltd 2025021120250211071512071514071514 0
0001213900-25-011925 6-K 3 20250211 20250211 20250211 Inspira Technologies OXY B.H.N. Ltd 0001837493 3841
000000000 L3 1231 6-K 34 001-40303 25607671 HATIDHAR 2 11TH FLOOR RA'ANANA L3 4366504 972-9-9664488
HATIDHAR 2 11TH FLOOR RA'ANANA L3 4366504 6-K 1 ea0230643-6k_inspira.htm REPORT OF FOREIGN PRIVATE
ISSUER Â Â UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Â FORM 6-K Â
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES
EXCHANGE ACT OF 1934 Â For the Month of February 2025 (Report No. 3) Â Commission File Number: 001-40303 Â
Inspira Technologies Oxy B.H.N. Ltd. (Translation of registrantâ€™s name into English) Â 2 Ha-Tidhar St. Raâ€™anana
4366504, Israel (Address of principal executive office) Â Indicate by check mark whether the registrant files or will file
annual reports under cover of Form 20-F or Form 40-F: Â â€™ Form 20-F Â Â Â Â Â Â Â Form 40-F Â Â Â Â
CONTENTS Â On February 11, 2025, Inspira Technologies Oxy B.H.N. Ltd., or the Registrant, issued a press release
titled â€œInspira Achieves Positive Results of Above 95% For Preventing Bloodstream Infections,â€ a copy of which is
furnished as Exhibit 99.1 with this report of foreign private issuer on Form 6-K. Â The first, second, fourth and fifth
paragraphs and the section titled â€œForward-Looking Statementsâ€ in theÂ press release are incorporatedÂ by
reference into the Registrantâ€™s Registration Statements on Form F-3 (Registration Nos.Â 333-266748Â andÂ 333-
284308) and FormÂ S-8 (Registration Nos.Â 333-259057Â andÂ 333-277980), filed with the Securities and Exchange
Commission, to be a part thereof from the date on which this Report of Foreign Private Issuer on Form 6-K is submitted,
to the extent not superseded by documents or reports subsequently filed or furnished.Â Â ExhibitÂ No. Â Â 99.1 Â
Press Release issued by Inspira Technologies Oxy B.H.N. Ltd. on February 11, 2025, titled â€œInspira Achieves Positive
Results of Above 95% For Preventing Bloodstream Infections.â€ Â 1 Â Â SIGNATURES Â Pursuant to the
requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its
behalf by the undersigned, thereunto duly authorized. Â Â Inspira Technologies Oxy B.H.N. Ltd. Â Â Â Date:
February 11, 2025 By: /s/ Dagi Ben-Noon Â Â Name:Â Dagi Ben-Noon Â Â Title: Chief Executive Officer Â Â 2 Â Â
Â EX-99.1 2 ea023064301ex99-1_inspira.htm PRESS RELEASE ISSUED BY INSPIRA TECHNOLOGIES OXY B.H.N.
LTD. ON FEBRUARY 11, 2025, TITLED "INSPIRA ACHIEVES POSITIVE RESULTS OF ABOVE 95% FOR PREVENTING
BLOODSTREAM INFECTIONS." Exhibit 99.1 Â Â Â Inspira Achieves Positive Results of Above 95% For Preventing
Bloodstream Infections Â The ex-vivo testing demonstrated significant bacterial reduction for the innovative IV
dressing technology aimed at preventing bloodstream infections in critical patients Â Raâ€™anana, Israel - February
11, 2025 â€œ Inspiraâ„¢ Technologies OXY B.H.N. Ltd. (Nasdaq: IINN) (â€œInspiraâ€ or the â€œCompanyâ€), a
pioneer in breakthrough life-support technology, today announced positive initial results from its previously reported
collaboration with Ennecure MedTech Ltd. to develop a novel bio-electronic treatment for preventing bloodstream
infections. Â In ex-vivo porcine skin model testing, the bio-electronic patch demonstrated a 95% reduction in bacterial
presence within 4 hours, with continued effectiveness observed over a 24-hour period. The technology, which uses
physical electric stimulation rather than chemical agents, showed promising results in preventing pathogen growth on
treated surfaces. Â â€œWe believe that these initial results represent an important milestone in our development of
next-generation infection prevention technology,â€ said Dagi Ben-Noon, CEO of Inspira. â€œWith an estimated 250,000
bloodstream infections related to intravenous lines occurring worldwide each year, we believe this novel approach
could potentially offer significant advantages in critical care settings.â€ Â The bio-electronic technology is being
designed to address several key challenges associated with traditional IV dressings, including: Â â— Prevention of
bacterial growth through physical rather than chemical means Â â— Potential for extended wear time, reducing
frequency of dressing changes Â â— Applicability to both skin surface and cannula areas Â â— Real-time monitoring
capabilities Â Testing was conducted following adjusted standardized protocols, including the AATCC TM100 standard
for antimicrobial performance, with results showing consistent bacterial reduction under active patches compared to
controls. Â About Ennecure MedTech Ltd. Â Ennecure, is a pioneer in the development of bio-electronic wound
dressing. At the core of the technology is a proprietary bio-electronic wound dressing designed to prevent bacterial
infections, while providing remote wound monitoring & infection alerts based on AI-driven personalized therapy. Â Â
Â Â About Inspira Â Inspira is an innovative medical technology company in the life support and respiratory treatment
arena. The Company has developed a breakthrough Augmented Respiration Technology (INSPIRAâ„¢ ART), a
groundbreaking device poised to revolutionize the \$19 billion mechanical ventilation market. With 20 million intensive
care unit patients with acute respiratory failure each year, many of whom rely on mechanical ventilators, the
INSPIRAâ„¢ ART system aims to revolutionize critical care by enabling patients to remain awake during treatment
while stabilizing oxygen levels without mechanical ventilation. The FDA-cleared INSPIRAâ„¢ ART100 system has
received regulatory approvals for Cardiopulmonary Bypass procedures in both the U.S. and for Cardiopulmonary
Bypass procedures and Extra Corporeal Membrane Oxygenation in Israel. The Companyâ€™s HYLAâ„¢ blood sensor
technology is designed to provide continuous, real-time blood monitoring without the need for blood draws, targeting
the \$2.5 billion blood gas analyzer market. The Companyâ€™s pipeline products, including the INSPIRAâ„¢ ART (Gen
2), INSPIRAâ„¢ Cardi-ART, and HYLAâ„¢ blood sensor, are currently in development and have not yet received
regulatory approval. Â For more information, please visitÂ our corporate website at <https://inspira-technologies.com>. Â
Forward-Looking Statement Disclaimer Â This press release contains express or implied forward-looking statements
pursuant to U.S. Federal securities laws. These forward-looking statements are based on the current expectations of the
management of the Company only and are subject to a number of factors and uncertainties that could cause actual
results to differ materially from those described in the forward-looking statements. For example, the Company is using
forward-looking statements when it discusses the potential benefits of its bio-electronic patch, that the initial results
represent an important milestone in its development of next-generation infection prevention technology and the
intended design of the bio-electronic patch. These forward-looking statements and their implications are based solely on
the current expectations of the Companyâ€™s management and are subject to a number of factors and uncertainties
that could cause actual results to differ materially from those described in the forward-looking statements. Except as
otherwise required by law, the Company undertakes no obligation to publicly release any revisions to these forward-
looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated
events. More detailed information about the risks and uncertainties affecting the Company is contained under the
heading â€œRisk Factorsâ€ in the Companyâ€™s annual report on Form 20-F for the fiscal year ended December 31,
2023, filed with the U.S. Securities and Exchange Commission (the â€œSECâ€), which is available on the SECâ€™s
website at www.sec.gov. Â Company Contact Â Inspira Technologies â€œ Media Relations Email: info@inspirao2.com
Phone: +972-9-9664485 Â Capital Markets & Investor Contact Â Arx | Capital Markets Advisors North American

Equities Desk inspira@arxadvisory.com Â Â Â Â Â GRAPHIC 3 ex99-1 001.jpg GRAPHIC begin 644 ex99-1 001.jpg
M_JC X 02D9)1@ ! 0\$ 8 !@ # VP!# \$! 0\$! 0\$! 0\$! 0\$! 0\$! 0\$! M 0\$! 0\$! 0\$! 0\$! 0\$! 0\$! 0\$! 0\$! 0\$! 0\$! 0\$! 0\$! 0\$!
0'_ MVP!# 0\$! 0\$! 0\$! 0\$! 0\$! 0\$! 0\$! 0\$! 0\$! 0\$! 0\$! 0\$! 0\$! M 0\$! 0\$! 0\$! 0\$! 0\$! 0\$! 0\$! 0\$! 0'_ P 1"] -0# 2(A\$!
Q\$!_ \0 M'P 04! 0\$! 0\$ \$" P0%!@<("0H+_ \0 M1 @#\$ P(\$ P4% M! 0 %) 0(# 011(1(A,4\$&\$U%A!R)Q)Q##*!D:\$(T*QP152T?
D,V)R@<D* M%A<8&1HE)B7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ(C)RM+3U-
76UJC9VN'BX<3EYN?HZ>KQ(O/T)?;W^/GZ_ \0 P\$ P\$! M)M 0\$! 0 \$" P0%!@<("0H+_ \0 M1\$ @\$\$! 0#! <%! 0 0)W \$"
M Q\$\$!2\$Q!A)!40=A<1,B,H\$(%\$*1H;'!2,S4O 58G+1"A8D-.\$E\1<8&1HF M)R@I*C4V-S@Y.D-
\$149'2\$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.\$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM::WN+FZPL/\$Q<;'R,G*TM/4 MU=;7V-G:YN/DY>;GZ.GJ\O/T)?;W^/GZ_ JH # ,!
(1 Q\$ /P#^ _BBBB@ H MHK!T[Q5X8UB^NM+TCQ'H.J:G8AC?:=IVL:??7UF\$<1L;JTMKB6XMPKD(QFC3 M:Y'G!(!%-
)N[2;2W:3:7JTFE[;2LFTF]JDVDWZ)M7^5S>HHHI#"BBB@ HHKG M]6\6^%= N;>SUWQ-X?
T6[NP&M+75M9TW3;FZ4L4#6\%YM6<6H:/J5AJUA-GR:[3+RWO[.7:<-Y5S:R2PR;3P=KGIX->3_ '
M_6 B5X=^&.IZQ\8[>;QM;Z]X(M[2WNO#%YXOCETG5?&WA_1_\$KC1+#5=&NI M7L_#NH:I]*72WRQ6!L_MES%-
>0S1M4(.%O\$NB0>)OBL/\$5E>W4 AR;6-4OH[7P<_@#Q-X8B@TN_C;74
M9Z;XYLY+EK30U2OT"JZ]">'J.E.5.4DD[TJD:L+2O;WX-QO97:O=7C>S=E% M&M&O!5(*
<8MM6]J0E3E=6O[LM;7=D]G9VNDNFRBBBL34**** "BBB@ HHHH_ + MC_@MAJVJZ*_ P2@_ ;QU?0]5U/1-
7T_P#9]5W.GZMHVH7FE:I87*2V&RXL=1L M)K>M)UR0LUO-(' 2 V"0?R0^'/BWQ;)_ P &DU_XPD\5^*)/%X_8:~*%^/%L
MGB+67\5" B; >+DBOAXC>].LB\BC1(XKH7OGQQHD:2*B]H_6#_@N+_RB/ ;] M_P"S= %O_HVPK]?_ (;?J@FH?\
9A_Q4_ \4X\85]7ED8O*<"W%-_ZVX"-V MDWRO"TKQNTWROM>WD>'C&UCL0DVdleQ#6NS]K+7U\S]?'^"6O@?_ (*!?
/%F M/V4/@_ \LQ1_ 'KXG_LG?[\$]?V6/#< PX^~?Q3%Z_J-]+KZX%S:>\$/'VC^(\&L[^WO;J_TG3UFLFUC3?
%= _>6VF^&/O_P".W_!J MM\\$ _A[X U3XE?\$_] _P!H_P#:C^#'[6G@33KCQ\ _#SQ1X@^*T>J;;XO6/;:
MR7UCI&LZEH>A>%=?_W6NWD*6<'B#2=6^QZ5<7*W%)H>J6:2VK?H]_P;A^#M M)]'_ /!&W]CQM,M(+;;Q;I'Q*`;S-
%&J27^K^(\B]X[DEO+IU_ ,TZVEO962 M2/EA:V=M#G;\$H'[AUFG\$&.P>;8ZCETX8+!T_=B8?5:5*BZ6)<:TU6GC%.E.
M6)EB)^TYU5DX0IRC2I1IQA\$RP&4X?\$9?A:F-C+\$8FKAJ4G7G.2J47*G>"P_ + M*,:/LDX\KA&[DG*3E>Q^&?_ P0_ X*+?
\$;_ @H7^Q7>W_ ,>2C_M(?L[_!!U M/X'_ !FO_L<&G7'B?4-'T^QU+PYXSU#3;2.*ST[6M:TF\?3O\$=K:1Q6C^M)!
MUJ^L[>TL[VWM8/W,K^1[_@V_P!!^/'_ 6PT&WQ'INF_MOS_9+=1A(BOC/X MYV&44?*N;;PM8R%
&V%!T45_7#7E<OX>CALYQM/'TXXTJ,I4:~4=(4EBL-AL_MYZ<%TA"=>:BME&T59))>AE-
6I5R_#RJ\$=2I564YR^*;H5:E'F>JVU!7=VW: M[;DW_*;XY^+/[8?_!8G]M;X^?LX_LV?' +5OV(;OO+K>A>
(&_ ^?)>TKPYIOA;1&U44N-7NO M(O?T_ 8L_P""ONJ_LA_'OP_\QD;J^!O^#:. [^U^ (?^"H&2"T/[46EQ
M%"N"Q"ZI\5\!FZG#;L_G 8MCDG\ 4[7XQP]P;E>95:%F>PQN8<13S/%8ZCB_M,1F>9K#Y>L-F&+IX'"X+ 4L=1P-
+#86A1I)4Y86HJTG.=;VCEK_H#XX_2)XZ_MV(9S]'7PKK<,\&>#N"X&XX5S/)\IX'X'JYOQ?/'N'^'9YF>:XZ=3&4<_P/?
\$NKZ[X6_92^!7PP^*/Q9T_QQXMT33M5.MLV>@:A=GQ7HNEZ3J-KI\LMG/!IVE^&M+N_\$^H:)-IG[7+:_P:9_LK>,)G\O
M_M1_M=?MD?'OX[:XK7_B?XJ-X^T#18YM?N562ZOM+TKQ-X9>ZSY:W1+P&8O#Y6_MUE[CA=:5*_ \$S2?
C=X]_: _X)4^-_&>F^#_ ![X)\&/'7\,%E\0?A[XW\+ZG>Z7=76@^)YO#6L:]J^F:C8
M36VH6\$UQIU]\$S!)8+JW9Y+>81R+)&/5_ ^"SWA?P1XO\ _^"5/[>NE?\$%+-O#]
MK^S7\1_ \$5O+>JC):>*"/>D/XG\\$7MOO_ .7^T\9:3H4^GA")9+U((H\M(?P_M#^".M>*-
;_X,\?',OBDSM+IW[/ 'QET/OI+C>?PIHWQ\06'AT([Y:2W@T^&_M.VM3DJEM!%%'B-
(HSCFM+*!K8[\+Z4ZDL+5RO\$8RA"%G2;I5*<R);R_ MDJ4^>,X0;?*T^5VT?VS^S-XG\3W7_!K7!XKNO\$WB.Y\5G_@GE\
<2/BFXUW5 MIO\$W]HP:>=\1#J!(027);N+^_QQF"]%X+F\$QQ^5*GEIM_#3_ ((X_LB_M1?\ M%)?
V6?"7P=:_*:_)^+GPL_X)Y_LE:QXA+3:3#_ \$VHXCX_B_M1_&[QIX@U/XC_M:Y=>-/_&7B7^VH;C0/AKH'BG1-
(M(-2L=O5O^#6KPW9Z#_ P_\$=/@A?6T*12^+?B+\\2M;T_32'JSBST&SA#\$DB.%%&%4
=\$L7+\\MXBQ%"_.*7%"I8:O*G3G_M/'RG3QO/5H\)\1C55*,H4Y)?\$7CCXG^*1'=ZEXJ\72:+9:-\$?!GPV\0Z!I\F
MC^&+=TAM5FB\Z#_L&L>)[S6Q\4_ G_@WD_: _X*#:9IO[4'_!9_JL+JH#7/ MB;\1[2/Q+9?L)?
#S7],T'3_A=I&KA+_3_#FL2ZGI>N^\$ _#%:_VJ]>>!_7@_M_2M\2C[%<^(-7U*.[DCZK_ (+)Z=IOCK_@X_-X(C?
#OXE)%>?"J.IXDT[2_M]4"RZ)?^_H_B-K>HVMM+:SYM;F;J_U_PA\K&:!T?[0DUK;2*Z3A#_8%7#B,Q MQ.5X'
8G#5+9KG5.OF..S2<*=3%?'+_A_ _,' "0: [^R7\;->L/%_@#XY_M:%I6;W4_!UN-*LO#&AWNKA:PM!H^E>
(/#EW=W<@31O&7AC53:7E>,?&YW_M[6WC]/LW_@JE_P%?.CIXAA:>\$=.)'PW\'^+X_A+XC\5ZWKNF?#?7Y?%ME
MH_B/0)T_498[33H]/6M-U*&!8M,T^]CLVBMKZ&.Y2>,?VJU_(O_,\$?/#'A_M+P=_P<&?_%Q=
\\6UE9^'H3HFII9Z="96FM>(_&UAXE\66\$),(4(C\6ZO MK@EAC54@G,L(13&5%X7-
*N993Q!"0AB,92RZE*GCW3IQQ\$J+Q^%C.A7G3IT
MU6M/EG1J3C[6"J]3]I*\$K)5L#'[X[*WA)RXH:>)]G&IA%*4J7.J%24*E)3E)T_M^L:D8R4))1=KG]3/QI^D'P<^%GC?
XG7&C7'B&P;HLFK?V':7EOI]QJDHG@_MMH++^Z22WLQ+/<1A[F:.1(8]TA1]NT^<>#?
VE_#%Y!XPMOBM!H_P=U_P5\0 MK'X:W]GK?C+1=7T'6_\$NK^%= %9:/9^\$/\\$\'':=#XAO;S1=VD^F[(HKB?J/VD?
AKK'QB^!7Q.^&/A^72(=9\9^&+G1];/7Y+F+1))Y[>_M;[JLMG:WUU%8W200;7,D%G=2)',S+!+C8?G#X;_
+*OBOPYXLTCQ1<:7\ _M_AVU^/FG?%NT^\$W@JXU/5_"/@^VL/@UXR^'>I:EX?O=0\Z'+XP\8>)/\$=
MAXBUQK;0M\$TRVCTN&:"[U9[R/O/C3Z\$^H9?CY\%(;3QA?2?%/P,MIX_O+?3_M_&
<_ "1Z:R>;V\OI=+M+;4MLY,4MUJL%Q15N%#B?5+6[TV(M?6MQ!%X_P#\$_M+J]M3X-^"I-:L]*UK3O&>HZ7*-
\$^,UI_8VO:.NC:QX(UKQ5'X734++>6Q<7,. MRSW2:Q=SM;M9Q:9%YC7(=F6/YT\ L@?&CX<^%;72?
#>IZ>GBOPCI_ACP'9^_M.A;OB'#J7Q"^\$VG^-&[2: X8T^RG\&7T'P-O]9MX=.NKK4_"TOBN]CU6/4]
M/TJ]TO3]074H&Z^Q;6M\#?:X*;4OA[>)]JGP7U'X<>([R;6_ \$JVFE:O#\>_M=5^+VF36;ZGH%S?^*M*U/2];N-
_U._U>;3=3CO[1;^:4DOIA/_N'W^_!O@#_ M63X\K07]62VTZ423:Y,M9LM8\+P6WB+Q;J]9?%=G%.VHK-%8_ \$]7F?
0O@MH\9R(K!D%W9^<= M+EU#41&SQ#17B:WEFO-UJOGGQ^!FO?#73M%^)%WXB&&:>GP]M_V3SI^I>:'
MXRUCP_?:S\%M.^)/AK6K378?"/AS6-8T?1+N/XAP7_AO7;32+]-_U/2[>ZU2 MSM+9_X/T(*^+?"_CG0-\
%7@SQ!H_BGPUJ]SMINN#J%#M]FE7PM;J>QNO_MLM]9R2V\QMKVVN;.X5'+075O-;RA)8G1>AKY_8]@^)^5E\O
47B'P_H6E^'_M-7LOBCXKU"=QXCT7Q(OB/Q7\8_ '%B70%T_PGK>D03V7A+5_"NLOK4\$VMWUIX
MDM&FTVSO='626[EM_K^@_HHHH_*C_@N,RK_,\$COV_68A0/V=_%N2Q_?6_M'4G@5^/WPVD3_B\$"U"3>FS_A@[X]?
N&S\<^, 3NSC&>.06OZK/7@/P5\3_M_""B#X?_!')^?^?7@;Q9ITVC^)_""BW2+^7_#?B'2K@J9].UG1M3@N;#4;
M*8HIDMKJ"6%RJED.!7'6WP_!UEV'6_9ZM/A#-\;X\$H%WX5;X.P>#=_B^&_MC>&KZ>:ZO=_;P6EB/#YT>[N;B>XN-/A]
JEFFFFEDDB9G8GV<)FE/#8+#X65*I_M*5'.L-FCG&4%&5.A2A3=%)ZJ]I)Q;4G[B3UU//KX*57\$5:RG%*I@*F#46G=2G_M-
R4VUIR]]FMSR?^#?J;E;_@C;^PBRL&4_#?Q)@J00G>&_""^@61V/9UP8[1Q>-Q>*C%PCB<5B,1&\$_MFG*;U:=11DXZ-
Q4TFUHV;0ZL-2=##T*+>DZ-&G2MG: ^NI_&_M;_P;^?&P/_&7_
<&_+^XEZE<9V/A!^U/XN^&(CGC4M/L+G5[W3O"]_A+_MQ3^T3K6MW=MI=@DM[?SP6%E<20V=M&]Q<.GE1(SL_?
K3XX?^67_3CTX&X: M^)+O[GJ[^?7QI^%YI-W?:#OP<_PSU_PEH=XXINX6@T5_ \$>N>)!IYM]'AOI8
M)KRWTBUU76KZ)#9Z;I\MS,KQ_O\ ^'OV4?V9/"6D_%K0?"_ [WP=\.Z)\>Y= M2F^_
VDZ+\. "NFZ=\6YM8&J+JLOQ%L[32XK?QA]J2ZYK(O7UV.^:Y&JZ@)B_MVN??ROPZ_87_&+/A%KMKXH^%W]?[-_P_\

\$)A(DVG^)/"7P6^'>AZ I\? MW)-/UFP\0ZE8.IYW6ES"20"22HQZ.98_9CB,5BYX?%PK55AHT5&M05.\$:& M"P^&E[1
M%?BW^UW\3)/C#J7A/6[*33-TJ=4N='UGQ'=ZIXB\53:/=1
MQW>F:=K>EV=Y%!>17%M!_0C117S]&C3H4XTJ4>6G#FY5_BE*J18;"83#8>GS>\XTN9 MZR:C FR L3?M%_M6_L*?
\'_ /@J+^W1\' A\'KWQX_9?^&?[6GQ: ^&7[\'PX M\%RK<^_], ^\'OCGXT_ %?#?"/Q1T#160^?+X!U7PUJLTFK@M96-
KJ5_I6O2Z1H MVO3: IG]AWPM_P"" ?\ P2)^*O@2R\>67[:_PK\ \$PSV*7E_X4^*%SJ/[@\'QUH MDI4-+I^H>&-\'?
M%WPG\5^)M"U/[J?J]?6/#^N>\'A_I_@/0-;MK^"V1-1M;/4]. ^\'UGJEG::IJ_M5]KUII>O? \$#6-+T?P?
X0T2YM;J_O=0_8S_@IQ^SUX#_9*_X_- /VE/V;?ALDD M?@?X*_LCV?@+1+F[5([S4TT6^VQ7^OZF\$8Q#5? \$6J-?:
[JS1MY;:EJ-TR85 M@*_8#X)?L]_O\FOP;!V/V?_A%\. _@UX)@D68>&_AQX2T7PGIEQ\$?4-1>ZO9\$ 5[A@_!V?
CSP#X^*7@_P_0?#W\XD^\$?#GCWP)XK ML\'TKQ/X.\7Z-8>(?#7B#3)\'CEDL-
8T75(+G3]1LWDBCD:WNK>6(O&C%-5&=6-3%8O\$*11E5Q&)K*,::JRITE2I0A%4:./=
MC=N4GZ5/+JKCBZN)K1K8W%X>6'=2,)0H4*7+)0I4:; C()\'!!!) #Q7[4Z5\ \$?@[H?PG\'P\'T;X7> =*^": M^&[_ ,\'#X3:?
X4T2T^\'8\)ZHMRFI>&QX0@LTT(:)I>7:W>F?8?L=PMS.)8F M\$KYT?A?\'*/AC\ \$O!>E?#CX/?# [P;\+OA_H;WTFC>"O
/AS2O"GA?2I-3O;C4 MM1?3]#T2UL].M\'OM0NKF^NV@MT-Q=W\$UQ*6ED=CGBLUIU\'F.%C1J1ECBBE"UG[UV?
AQ_P_P!E-Y[3]LS]BWQA)\5/@U%I MDT%EK?C\'28[G2=8U[P\'HE].T4*^*[35?#7A[Q9X(BO)EL[S6M\$GT! *_X2-K
MB\'S7]@;_ (.4_P!C\'XU>!\;\'P-^VQXOM/V+_VK__?AKXL>"OBWI6M^%/\!NI M>+-(\'V\'6=4\+^+(+ZP-KH,=Y>P27%SX-
\9OH?B+P_=32:7&FLV[K\'JMU_2C7Q M#^TA_P_\$V/V"OVO-:C\3_M(?LG_!;XK>*XXUA/C#7?"%G:>_IH41(XH+OQ?H
M9TKQ+>V\,<:QP07>J3PP("D*(K,"\'F6#JX&GEN8>O6HX:=2I@<7@ZE.&+P MGMI*5:@XUTZ.(PU2:]HJZ1\'+?
V&-7E_ ;U_! M^(GF>&/@U)\)/@9I.N>* _#DGC+4T-KHU_XO_%=C8)ILVC:?=RK>WVC^&+K5=
M;O8+66VG_L*TEEURQ_)#_@V?\'\$?&[X;_ /!5G_@J7X,_8U2SUC]HG3_\'X M;U7XVW]EJD&LPS?
\$GQ;\'2\'8^*!_:5J!;W4EOJ/B\'2UN&LJ]A%VK@![.Z M\77R7OB>XLI-JF2SEU9K61E5WB9E!\'L/A#X ? [X?_\$7QW\7O
WPA^&_A#XJ_M?%\'RO^%D? \$;PWX-T#1O&OCSR94GA_P"\$N\2Z?80:OX@/J:...5/[4N[G;(BN,M,H(Z%FV6X7_9EEV P6(4,?
AX4YXS%5;.\5.K3Q%*K#FC2C&C1PT(0FE1H\J]2_M=6:J5*EHQBLW@,77Q6\$QF*Q%-SPM6=2K)M>_)QC&*Y8
MQW//_P\L_5-8T7]EKXV:GH%\J]6FZS;># +C^S[S1]4NM\$U1+B:JLK<1V6L64L M-
WI<[RLK6]W]O+\'+"8SJ P*5\^./BS\3OV>?#L6@>!/ASX2\+/IOPN^(GQJ_M\2^\'B+\'0/"?Q/O2/"OCCP+X671-*7?VO-
<1#Q!I BD7T=S:JTT"XMDB31_M[U99U\'Z!>+?"7AKQWX:UKP=XQT6P\1^%_\$5A-IFN:\'JD N-/U/3[@_36MW"Q_M DB?
)&000&4@@\$>:9^SW\%=\'TFZT.Q^\'/AU=*O=)UK0;NTN8])06XT7Q?
MZ3JFN:5++J\$]U.UAJ>HZ% H]Y=6IE\F2XTZUDV@QBOFCV#Y8OOVC_(_/J(\"
MZ3IGP:3QQ8_\$\'XW^\$-5U_5;3QJGA"2P^%O@/PM\0-(O++2+?6O[7@NM3M?\$T
M>B:KJJUJ2WMI[:76;7S(MFD295E^V)\5/%.DZ;XV\)>#/_EMX5N=>^#7PX E\ M,:]=Z))XTNOB%\;OAWX6\5Z%JEG?
6D]II<\'A/0=<\>>&-,NK";3])4U_1K/Q_M#K%IJFDR0V5E-J&?\$G]E?X5_\'%Q1X2UOQ)H6F2Z-H.N^.?%&O^&18.EIXS\1
M>./#E^%;K6-6O;6]LJ].[MM,T]WMY2HGCU*TS8W: ?9\AO0^\'"PC?QMI\'Q%_M_P"%>^&\$\9Z%9Z?8Z1K<.G1V[V4.D6-
SI>CR164!CTYKS1M+O+K2]&U&2S?4_M-)TR>73].N:;S8PT ? &D?\'!0WQ-JV^\'M_&@7&EW>D^&?\$?AX6]_J3:AKF
MC^#_(:Z]XY_:9MHXG816^J_#?5M%C\ (Z\$ _UQ#-JFH0#6%20""3N/"W[47[0_M_B31_!BR?
#3PSH.H_\$\'XA?"WP]X9\5>* _#7CWPKX1N-^\'(^@7QKXOU^\'3](U_M&_EUWQ#K/[@67PE;V@U:UO=-
T\'Q9!KUA;/PZ"\'T5RD7V1HOP/^#_ARX/VW>A?#
M;P;I5SX4/CT^&YK+0K&%] %_X6CJ:ZS\11I^V+%NOC35\$6^\'1*HVZG<#?TO3M2TC2[[28KNXN(]_M)73-+UC5-
/TVSTY;6PL+. N;>TM88I"\'M\'Q3X6_ ;5^,/BSPW-XNL?A+!8^&O_M\'%SX5TCX7^([>V>+])#_^\'?\$GC;XU:#\(_#^C>-
M;NKIX?&P:P\1Q>,[R]_M\$PZ+##"- \$U7PV%\ZYL-9/T=^R9J?B_4/"OQ37QWK-GK?B:P_ :&^&-&E7EUI CZH
MNC1QZ=XI>""ST&SUG4-4U#3=\'LX?+BM=,EO[I;\'YH8Y7C"\'L>Z\'[-GP*\'<(/_MAEX9\$\'Q\'BN(O&=FL%PMAJXN]477;J1-
/%R++>2[BXUU4UV6ZT>WT^Z?7\$36&F_M.I(MT-SPK\ \$OA/X(F\ -W\'A+P\'H&@3^\$9/%<_AV;3K9X9=-N?\'3V\$GC&[20RL
MUQ>^)9=,L9]9O;LW%W?7%NMQ-.TSR2._>IT444_ %%%!!1110_4444_ %%%M\'R%^S5^PC^RY^R)XY^/7Q(^\'PW_
.\$&\8_M->-7^(7QIU;_(2;Q5KW_"7>_M+9-6\1ZVVJ?9/\$.M:I9:;#J?BS7KC[]HEOI]F/MOEB_100)']>T45I5K5:\W
M4K5*E6HU&+G4G*